Survival Efficacy of Adjuvant Cytosine-Analogue CS-682 in a Fluorescent Orthotopic Model of Human Pancreatic Cancer

Cancer Research

Volumn 64, Issue 5, 2004, Pages 1828-1833

  Katz, Matthew H ^a   Bouvet, Michael ^a   Takimoto, Shinako ^a   Spivack, Daniel ^a   Moossa, Abdool R ^a   Hoffman, Robert M ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ANTICANCER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 C CYANO 2 DEOXY BETA DEXTRO ARABINOPENTOFURANOSYL) N4 PALMITOYLCYTOSINE; 2' CYANO 2' DEOXY 4 N PALMITOYLCYTARABINE; BRILLIANT RED FLUORESCENT PROTEIN; CYTOSINE DERIVATIVE; RED FLUORESCENT PROTEIN; UNCLASSIFIED DRUG; 2' C CYANO 2' DEOXY 1 ARABINOFURANOSYL N(4) PALMITOYLCYTOSINE; 2'-C-CYANO-2'-DEOXY-1-ARABINOFURANOSYL-N(4)-PALMITOYLCYTOSINE; ARABINONUCLEOSIDE; CYTOSINE; DRUG DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER MODEL; CANCER SURGERY; CANCER SURVIVAL; CAUSE OF DEATH; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DRUG EFFECT; DRUG EFFICACY; FLUORESCENCE; HUMAN; HUMAN CELL; MALE; METASTASIS; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SURVIVAL TIME; ADJUVANT CHEMOTHERAPY; ANIMAL; MORTALITY; NUDE MOUSE; PANCREAS TUMOR; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ARABINONUCLEOSIDES; CELL LINE, TUMOR; CHEMOTHERAPY, ADJUVANT; CYTOSINE; HUMANS; MALE; MICE; MICE, NUDE; PANCREATIC NEOPLASMS;

EID: 1642417403     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-03-3350     Document Type: Article

References (25)

1. Huang, J. J., Yeo, C. J., Sohn, T. A., Lillemoe, K. D., Sauter, P. K., Coleman, J., Hruban, R. H., and Cameron, J. L. Quality of life and outcomes after pancreaticoduodenectomy. Ann. Surg., 231: 890-898, 2000.
2. Nguyen, T. C., Sohn, T. A., Cameron, J. L., Lillemoe, K. D., Campbell, K. A., Coleman, J., Sauter, P. K., Abrams, R. A., Hruban, R. H., and Yeo, C. J. Standard versus radical pancreaticoduodenectomy for periampullary adenocarcinoma: a prospective, randomized trial evaluating quality of life in pancreaticoduodenectomy survivors. J. Gastrointest. Surg., 7: 1-9; discussion 9-11, 2003.
3. Burris, H. A., III, Moore, M. J., Andersen, J., Green, M. R., Rothenberg, M. L., Modiano, M. R., Cripps, M. C., Portenoy, R. K., Storniolo, A. M., Tarassoff, P., Nelson, R., Dorr, F. A., Stephens, C. D., and Von Hoff, D. D. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol., 15: 2403-2413, 1997.
4. Bouvet, M., Gamagami, R. A., Gilpin, E. A., Romeo, O., Sasson, A., Easter, D. W., and Moossa, A. R. Factors influencing survival after resection for periampullary neoplasms. Am. J. Surg., 180: 13-17, 2000.
5. Ishikawa, O., Wada, H., Ohigashi, H., Doki, Y., Yokoyama, S., Noura, S., Yamada, T., Sasaki, Y., Imaoka, S., Kasugai, T., Matsunaga, T., Takenaka, A., and Nakaizumi, A. Postoperative cytology for drained fluid from the pancreatic bed after "curative" resection of pancreatic cancers: does it predict both the patient's prognosis and the site of cancer recurrence? Ann. Surg., 238: 103-110, 2003.
6. Iacono, C., Accordini, S., Bortolasi, L., Facci, E., Zamboni, G., Montresor, E., Marinello, P. D., and Serio, G. Results of pancreaticoduodenectomy for pancreatic cancer: extended versus standard procedure. World J. Surg., 26: 1309-1314, 2002.
7. Yeo, C. J., Cameron, J. L., Lillemoe, K. D., Sohn, T. A., Campbell, K. A., Sauter, P. K., Coleman, J., Abrams, R. A., and Hruban, R. H. Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma, part 2: randomized controlled trial evaluating survival, morbidity, and mortality. Ann. Surg., 236: 355-366; discussion 366-358, 2002.
8. Pedrazzoli, S., DiCarlo, V., Dionigi, R., Mosca, F., Pederzoli, P., Pasquali, C., Kloppel, G., Dhaene, K., and Michelassi, F. Standard versus extended lymphadenectomy associated with pancreatoduodenectomy in the surgical treatment of adenocarcinoma of the head of the pancreas: a multicenter, prospective, randomized study. Lymphadenectomy Study Group. Ann. Surg., 228: 508-517, 1998.
9. Saltz, L. B., and Minsky, B. Adjuvant therapy of cancers of the colon and rectum. Surg. Clin. N. Am., 82: 1035-1058, 2002.
10. Garrett, T. J., Vahdat, L. T., and Kinne, D. W. Systemic adjuvant therapy of breast cancer. J. Surg. Oncol., 64: 167-172, 1997.
11. Neoptolemos, J. P., Dunn, J. A., Stocken, D. D., Almond, J., Link, K., Beger, H., Bassi, C., Falconi, M., Pederzoli, P., Dervenis, C., Fernandez-Cruz, L., Lacaine, F., Pap, A., Spooner, D., Kerr, D. J., Friess, H., and Buchler, M. W. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet, 358: 1576-1585, 2001.
12. Klinkenbijl, J. H., Jeekel, J., Sahmoud, T., van Pel, R. Couvreur, M. L., Veenhof, C. H., Arnaud, J. P., Gonzalez, D. G., de Wit, L. T., Hennipman, A., and Wils, J. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: Phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann. Surg., 230: 776-782; discussion 782-774, 1999.
13. Katz, M., Bouvet, M., Takimoto, S., Spivack, D., Kobayashi, T., Moossa, A. R., and Hoffman, R. M. Selective antimetastatic activity of cytosine analog CS-682 in a red fluorescent protein orthotopic model of pancreatic cancer. Cancer Res., 63: 5521-5525, 2003.
14. Matz, M. V., Fradkov, A. F., Labas, Y. A., Savitsky, A. P., Zaraisky, A. G., Markelov, M. L., and Lukyanov, S. A. Fluorescent proteins from nonbioluminescent Anthozoa species. Nat. Biotechnol., 17: 969-973, 1999.
15. Katz, M., Takimoto, S., Spivack, D., Moossa, A. R., Hoffman, R., and Bouvet, M. A novel red fluorescent protein orthotopic pancreatic cancer model for the preclinical evaluation of chemotherapeutics. J. Surg. Res., 113: 151-160, 2003.
16. Bouvet, M., Wang, J., Nardin, S. R., Nassirpour, R., Yang, M., Baranov, E., Jiang, P., Moossa, A. R., and Hoffman, R. M. Real-time optical imaging of primary tumor growth and multiple metastatic events in a pancreatic cancer orthotopic model. Cancer Res., 62: 1534-1540, 2002.
17. Harris, D. T., and Mastrangelo, M. J. Theory and application of early systemic therapy. Semin. Oncol., 18: 493-503, 1991.
18. Yeo, C. J., Cameron, J. L., Sohn, T. A., Lillemoe, K. D., Pitt, H. A., Talamini, M. A., Hruban, R. H., Ord, S. E., Sauter, P. K., Coleman, J., Zahurak, M. L., Grochow, L. B., and Abrams, R. A. Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: pathology, complications, and outcomes. Ann. Surg., 226: 248-257: discussion 257-260, 1997.
19. Kalser, M. H., and Ellenberg, S. S. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch. Surg., 120: 899-903, 1985.
20. Bakkevold, K. E., Amesjo, B., Dahl, O., and Kambestad, B. Adjuvant combination chemotherapy (AMF) following radical resection of carcinoma of the pancreas and papilla of Vater: results of a controlled, prospective, randomised multicentre study. Eur. J. Cancer, 29A: 698-703, 1993.
21. Yeo, C. J., Abrams, R. A., Grochow, L. B., Sohn, T. A., Ord, S. E., Hruban, R. H., Zahurak, M. L., Dooley, W. C., Coleman, J., Sauter, P. K., Pitt, H. A., Lillemoe, K. D., and Cameron, J. L. Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience. Ann. Surg., 225: 621-633; discussion 633-626, 1997.
22. 4-palmitoylcytosine (CS-682). Proc. Am. Assoc. Cancer Res., 38: 679, 1997.
23. Hanaoka, K., Suzuki, M., Kobayashi, T., Tanzawa, F., Tanaka, K., Shibayama, T., Miura, S., Ikeda, T., Iwabuchi, H., Nakagawa, A., Mitsuhashi, Y., Hisaoka, M., Kaneko, M., Tomida, A., Wataya, Y., Nomura, T., Sasaki, T., Matsuda, A., Tsuruo, T., and Kurakata, S. Antitumor activity and novel DNA-self-strand-breaking mechanism of CNDAC [1-(2-C-cyano-2-deoxy-β -D-arabino-pentofuranosyl) cytosine] and its N4-palmitoyl derivative (CS-682). Int. J. Cancer, 82: 226-236, 1999.
24. Wu, M., Mazurchuk, R., Chaudhary, N. D., Spernyak, J., Veith, J., Pera, P., Greco, W., Hoffman, R. M., Kobayashi, T., and Bemacki, R. J. High-resolution magnetic resonance imaging of the efficacy of the cytosine analogue 1-[2-C-cyano-2-deoxy-β-D-arabino-pentofuranosyl]-N(4)-palmitoyl cytosine (CS-682) in a liver-metastasis athymic nude mouse model. Cancer Res., 63: 2477-2482, 2003.
25. Neoptolemos, J. P., Cunningham, D., Friess, H., Bassi, C., Stocken, D. D., Tait, D. M., Dunn, J. A., Dervenis, C., Lacaine, F., Hickey, H., Raraty, M. G., Ghaneh, P., and Buchler, M. W. Adjuvant therapy in pancreatic cancer: historical and current perspectives. Ann. Oncol., 14: 675-692, 2003.